The nation of Zimbabwe has rejected a substantial American healthcare agreement worth 367 million US dollars (272 million pounds) over five years because of Washington's request for confidential data.
This rejection came to light after a official document dated December was disclosed, revealing that Head of State Emmerson Mnangagwa felt the arrangement was "skewed".
A government representative later stated that the United States was demanding access to biological samples for research and commercial gain while was not willing to share the benefits from future treatments.
"We will now turn to the difficult and regrettable task of scaling back our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the United States had furnished over $1.9bn for health programmes to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has called for more negotiations to secure a agreement suitable to both sides so the nation's vital HIV programme can be sustained.
Wider Implications
Zimbabwe's decision comes after a similar case in neighbouring Kenya, where a court blocked a similar health funding agreement following concerns were filed about the security of citizens' health data.
After returning to the presidency recently, US President Donald Trump has reduced overseas assistance and closed the key foreign aid agency.
The agency had administered assistance for the American government, but Trump claimed its expenditure was "wasteful" and his administration was seeking government-to-government deals to boost transparency and responsibility.
Based on reports, 16 nations in Africa have to date signed these new agreements, representing more than $18.3bn of fresh investment.
Details of the Declined Agreement
The funds for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this partnership might have yielded significant benefits for the people of Zimbabwe, particularly the 1.2 million currently receiving antiretroviral therapy via American-funded initiatives," the Ambassador said.
However, official spokesman Nick Mangwana argued the arrangement was "unfair".
"The proposal required Zimbabwe to provide its biological resources and data indefinitely, without any corresponding assurance of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could be developed from that provided information," his statement read.
"In essence, our nation would supply the raw materials for medical research without any certainty that the end products would be accessible to our population should a new pandemic emerge."
National Interest and Global Health
Mangwana further said that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral health agreements were upending structures previously set up through the international health agency.
The spokesperson cited its Pandemic Benefit-Sharing framework created to deal with potential pandemics.
"This framework is intended to ensure that when a nation contributes its data, the resulting advantages – including medicines and cures – are shared equitably, not monopolised exclusively by those with the capability to create them."
These objections regarding the US deal "should not be misconstrued as hostility towards the US," he added.
"We encourage further dialogue with our American counterparts on how future co-operation might be structured in a way that respects the sovereignty and dignity of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the government's concerns, but suggested that talks should continue considering a large portion of the country's HIV programmes depended on foreign aid.
"If technical issues exist, including those relating to information security or agreement terms, these can frequently be addressed through detailed discussion and negotiated safeguards," the group commented.
The situation highlights the ongoing tensions between receiving vital foreign assistance and protecting national sovereignty in an ever more data-driven world.